Neglected Tropical Disease News and Research

RSS

New drug for sleeping sickness approved in the Democratic Republic of Congo

Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC).

31 Jan 2019

Combination therapy shows high efficacy in treating people with leishmaniasis and HIV

The results of clinical trials conducted in Ethiopia by the Drugs for Neglected Diseases initiative, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options.

18 Jan 2019

Novel way to efficiently deliver anti-parasitic medicines

Scientists have developed a new way to deliver anti-parasitic medicines more efficiently.

12 Dec 2018

New collaborative partnership in quest of novel antibiotics

The Global Antibiotic Research and Development Partnership, Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries.

12 Dec 2018

EMA recommends first all-oral treatment to tackle deadly sleeping sickness

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.

16 Nov 2018

Researchers identify genes that could help predict treatment outcomes for parasitic disease

Researchers at the University of York have identified genes in a parasite that could help clinicians predict drug treatment outcomes for patients with visceral leishmaniasis in Brazil.

1 Oct 2018

GARDP partners with Novartis to accelerate development of generic antibiotic treatments for children

The Global Antibiotic Research & Development Partnership and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries.

27 Sep 2018

Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.

24 Sep 2018

Clinical trial begins to find better treatment for chronic cases of PKDL in Africa

A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan.

12 Sep 2018

Effective vaccines for world's most prevalent infectious diseases are missing from pipeline

Many of the vaccines critically needed to fight some of the world's most prevalent infectious diseases are not likely to be developed, a new analysis of current candidates in the research and development pipeline has found.

5 Sep 2018

Researchers report challenges in reducing tetanus mortality

The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.

31 Aug 2018

Researchers develop new approach to study how tuberculosis infects people

Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected.

17 Aug 2018

Scientists discover potential new drug to treat two life-threatening tropical diseases

Derived from nature, a potential new drug to treat two life-threatening tropical diseases has been discovered as a result of collaboration between two Welsh universities.

5 Jul 2018

New guide published to help battle fatal disease caused by kissing bugs

A guide to help battle a potentially fatal disease transferred by a blood-sucking insect called the kissing bug has been published by a task force led by The University of Texas Health Science Center at Houston.

22 Jun 2018

Clinical study to find improved treatment for visceral leishmaniasis starts in eastern Africa

A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis has begun in eastern Africa, within the new Afri-KA-DIA Consortium with funding from The European & Developing Countries Clinical Trials Partnership.

13 Apr 2018

Open Pharma drug discovery project aims to develop new treatments for mycetoma

The MycetOS project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.

6 Feb 2018

SUTD-NCL team completes phenotypic screening of MMV Malaria Box against pathogenic parasites

A Singapore-India collaborative research project between the Singapore University of Technology & Design and CSIR-National Chemical Laboratories completed phenotypic screening of a large collection of potent chemical inhibitors (known as MMV Malaria Box), against pathogenic parasites Toxoplasma gondii and Plasmodium falciparum, causative agents of human toxoplasmosis and malaria.

27 Jan 2018

Leishmania genome study reveals the parasites adaptation to the environment

A new study, conducted by researchers from the Institut Pasteur in Paris and the Centre for Genomic Regulation (CRG) in Barcelona, have revealed that Leishmania adaptation is a consequence of reversible and frequent chromosomal amplifications.

23 Nov 2017

Leishmania adaptation to environmental changes results from frequent chromosomal amplifications

Leishmaniasis is an important human and veterinary disease caused by Leishmania parasites that affect 12 million people in over 98 endemic countries. The disease is now emerging in Europe due to climate change and massive population displacement.